Savant Capital LLC Boosts Stake in Bristol-Myers Squibb (NYSE:BMY)

Savant Capital LLC increased its position in Bristol-Myers Squibb (NYSE:BMY) by 1.3% in the 4th quarter, Holdings Channel reports. The firm owned 96,631 shares of the biopharmaceutical company’s stock after buying an additional 1,231 shares during the period. Savant Capital LLC’s holdings in Bristol-Myers Squibb were worth $5,465,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. AMF Tjanstepension AB increased its position in Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after acquiring an additional 39,419 shares during the period. Ritholtz Wealth Management increased its position in Bristol-Myers Squibb by 81.0% in the 3rd quarter. Ritholtz Wealth Management now owns 23,843 shares of the biopharmaceutical company’s stock valued at $1,234,000 after acquiring an additional 10,669 shares during the period. Exchange Traded Concepts LLC increased its position in Bristol-Myers Squibb by 18.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 26,468 shares of the biopharmaceutical company’s stock valued at $1,369,000 after acquiring an additional 4,064 shares during the period. Koshinski Asset Management Inc. increased its position in Bristol-Myers Squibb by 3.5% in the 3rd quarter. Koshinski Asset Management Inc. now owns 26,568 shares of the biopharmaceutical company’s stock valued at $1,375,000 after acquiring an additional 904 shares during the period. Finally, Sound Income Strategies LLC increased its position in Bristol-Myers Squibb by 46.9% in the 3rd quarter. Sound Income Strategies LLC now owns 2,770 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 885 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

BMY opened at $55.50 on Tuesday. The stock has a market cap of $112.55 billion, a P/E ratio of -12.56, a P/E/G ratio of 2.13 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The stock’s 50 day simple moving average is $57.56 and its 200 day simple moving average is $53.89. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.47%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Analyst Ratings Changes

Several equities analysts recently issued reports on BMY shares. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Morgan Stanley boosted their target price on Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Finally, Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.